The 12-month price targets, analyzed by analysts, offer insights with an average target of $23.58, a high estimate of $25.00, ...

Kenvue (KVUE), the company behind Tylenol and Neutrogena, announced that Thibaut Mongon had left the company, naming Kirk ...

Kenvue (NYSE:KVUE) recently experienced a 2% price increase over the past week, a move that coincides with notable executive changes. The replacement of the CEO with Kirk L. Perry as interim CEO, ...

Kenvue has five brands that generate over $1 billion in sales—Johnson’s, Neutrogena, Listerine, Tylenol, and Aveeno—as well as a number of brands that generate over $400 million in sales: Nicorette, ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

We believe Perrigo is in fine financial health. At the end of 2024, the company had roughly $560 million in cash and equivalents with about $3.3 billion in long-term debt. Its balance sheet was in a ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

So far this year, the favorite demand for activist investors has been a call for board changes, appearing in 43% of campaigns ...

After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price ...

Late June, 2025, 25 of the 55 Dividend Kings were tagged "safer" for dividends as they showed positive one-year returns and free-cash-flow-yields greater-than dividend-yields. Furthermore, YCharts 7/1 ...

Asian shares are trading mostly lower as worries about President Donald Trump’s latest updates to his tariffs weighed on ...

In a testament to its enduring strength and adaptive strategy, Johnson & Johnson (NYSE: JNJ) today announced a strong ...